WASHINGTON, D.C. -- The Food and Drug Administration (FDA) has announced the approval of Cubicin (daptomycin for injection) for the treatment of complicated skin and skin structure infections. These are serious infections, usually occurring in hospitalized patients, and include major abscesses, post-surgical skin wound infections, and infected ulcers.
Cubicin is the first approved product in a new class of antibiotics called cyclic lipopeptide antibacterial agents. Cubicin treats infections in a way that is distinct from any other antibiotic.
The approval of Cubicin is part of FDA's ongoing efforts to help bring new types of antibiotics to patients to make sure there are treatment options available for serious infections. In 2002, doctors prescribed an estimated seven million courses of IV antibiotics for patients with complicated skin and skin structure infections in US hospitals.
Cubicin is specifically indicated for the treatment of complicated skin and skin structure infections caused by susceptible strains of the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subspecies equisimilis and Enterococcus faecalis (vancomycin-susceptible strains only). Cubicin is not indicated for the treatment of pneumonia.
FDA based its decision to approve Cubicin on a review of clinical studies involving over 1400 adults that demonstrated the drug's safety and efficacy. The clinical studies demonstrated Cubicin was equivalent to standard treatments (i.e., vancomycin or a semi-synthetic penicillin such as oxacillin or nafcillin) in the treatment of complicated skin and skin structure infections.
Most adverse events reported in the clinical studies of Cubicin were mild to moderate in intensity. The most common adverse events included gastrointestinal disorders, injection site reactions, fever, headache, insomnia, dizziness, and rash.
Blood tests showing muscle injury were found rarely in patients in clinical trials. Most of these patients had no symptoms, and the blood tests returned to normal after therapy. Patients receiving Cubicin should be monitored for the development of muscle pain or weakness. Blood tests measuring creatine phosphokinase (CPK) levels should be monitored weekly in patients who receive Cubicin. Those who develop unexplained elevations in CPK while on Cubicin should be monitored more frequently.
Cubist Pharmaceutical Inc., of Lexington Mass., is the sponsor of the approved New Drug Application (NDA) for Cubicin.
Source: FDA
“Ongoing Assault”: How HHS Layoffs Have Eviscerated Infection Prevention Support Across the Nation
April 1st 2025Mass layoffs at HHS and CDC have gutted critical infection prevention programs, leaving frontline professionals overwhelmed, under-resourced, and desperate to safeguard public health.
Together We Rise: Why AORN Expo 2025 Is a Must for Every Perioperative Nurse
March 31st 2025From April 5 to 8, 2025, thousands of perioperative nurses will gather in Boston for the 2025 AORN Global Surgical Conference & Expo—a transformational experience designed to elevate nursing practice, build lifelong connections, and advance surgical care.
Vet IP Roundtable 2: Infection Control and Biosecurity Challenges in Veterinary Care
March 31st 2025Veterinary IPs highlight critical gaps in cleaning protocols, training, and biosecurity, stressing the urgent need for standardized, animal-specific infection prevention practices across diverse care settings.